Avalo Therapeutics, Inc. — Form D

Avalo Therapeutics, Inc. of ROCKVILLE, MD, a company, filed a Form D exempt-offering notice with the SEC on 2016-09-16. The offering totals $15.0M, of which $1.0M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (52)

Showing 25 of 52 people.

NameRoleLocation
Thomas AasenDirectorResearch Triangle Park, NC
Eugene BauerDirectorRedwood City, CA
Isaac BlechDirectorJupiter, FL
Phil GutryDirectorBaltimore, MD
Magnus PerssonDirectorBeachwood, OH
Behshad SheldonDirectorMalvern, PA
John KaiserExecutive OfficerResearch Triangle Park, NC
Ronald MarcusExecutive OfficerBaltimore, MD
Mariam MorrisExecutive OfficerDallas, TX
CHRISTOPHER SULLIVANExecutive OfficerNew York, NY
June Almenoff, M.D., Ph.D.DirectorRockville, MD
Mitchell ChanDirectorRockville, MD
Jonathan Goldman, M.D.DirectorRockville, MD
Aaron KantoffDirectorRockville, MD
Gilla Kaplan, Ph.D.DirectorRockville, MD
Magnus Persson, M.D., Ph.D.DirectorRockville, MD
Samantha TruexDirectorRockville, MD
Garry Neil, M.D.DirectorRockville, MD
Garry Neil, M.D.Executive OfficerRockville, MD
Uli HacksellDirectorWAKE FOREST, NC
Uli HacksellExecutive OfficerWAKE FOREST, NC
Frank A TortiDirectorMenlo Park, CA
Isaac A BlechDirectorCITY OF INDUSTRY, CA
PHIL E GUTRYDirectorBALTIMORE, MD
MAGNUS E PERSSONDirectorBALTIMORE, MD

Other filings by this issuer (5)

FiledFormOfferingSold
2024-04-09D$200.0M$130.6M
2017-05-08D$5.0M$5.0M
2014-07-21D$33.3M$16.3M
2013-09-06D$10.0M$6.8M
2012-04-04D$22.5M$22.1M

More